AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

Brief description of study

The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with unexplained strokes and atrial cardiopathy to see which is better at prevention of future strokes. The use of apixaban for stroke prevention in ischemic stroke patients like you, without atrial fibrillation, is not approved by the U.S. Food and Drug Administration (FDA) and is considered investigational in this research study. Aspirin is the standard of care blood thinner used for stroke prevention in patients


Clinical Study Identifier: s17-01117
ClinicalTrials.gov Identifier: NCT03192215
Principal Investigator: Jose L. Torres.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.